VivoSeq
Oncology

Other Solid Tumors

0

Pipeline Programs↗

12

Active Trials↗

10

Companies Involved↗

Other Solid Tumors is an early-stage landscape with 0 programs across 10 companies. The most active players are Ascentage Pharma Group Inc., Sichuan Baili Pharmaceutical Co., Ltd., Y-mAbs Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.

0 programs

PreclinicalS

Sichuan Baili Pharmaceutical Co., Ltd.

0 programs

PreclinicalY

Y-mAbs Therapeutics

0 programs

PreclinicalR

Rain Oncology Inc

0 programs

PreclinicalJiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.

0 programs

PreclinicalS

Shanghai Kanda Biotechnology Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

24

clinical trials

Recruiting8 · 33%
Completed4 · 17%
Active, not recruiting4 · 17%
Unknown status4 · 17%
Terminated2 · 8%
Withdrawn1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

24 trials

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT03454035·45 enrolled
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Recruiting·Ascentage Pharma Group Inc. logoAscentage Pharma Group Inc.·Phase 1·NCT03594422·100 enrolled
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Recruiting·NNuvalent Inc.·Phase 1/2·NCT05118789·359 enrolled
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06364410·48 enrolled
HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
Recruiting·SShanghai Ruiliyuan Biotechnology Co., Ltd.·Phase 1·NCT06515314·12 enrolled
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Recruiting·NNuvalent Inc.·Phase 1/2·NCT05384626·840 enrolled
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Recruiting·PPrincess Maxima Center for Pediatric Oncology·Phase 1/2·NCT04925609·65 enrolled
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Recruiting·BBetta Pharmaceuticals Co., Ltd.·Phase 1/2·NCT04930432·400 enrolled
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
Active, not recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT05393427·4 enrolled
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT00479128·80 enrolled
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
Active, not recruiting·HHarbour BioMed (Guangzhou) Co. Ltd.·Phase 1·NCT05167071·53 enrolled
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Active, not recruiting·AAllist Pharmaceuticals, Inc.·Phase 1/2·NCT05194995·48 enrolled
Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors
Completed·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT05279690·16 enrolled
Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors
Completed·WWashington University School of Medicine·Phase 1·NCT00660426·30 enrolled
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
Completed·Ascentage Pharma Group Inc. logoAscentage Pharma Group Inc.·Phase 1·NCT03080311·50 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)